FDA Draft Bioequivalence Guidance Draws Litany Of Brand Name Complaints
Executive Summary
Brand firms are weighing in on product-specific draft guidance issued by FDA, which the agency hopes will allow generic drug firms to design bioequivalence studies for their ANDAs without having to consult with the Office of Generic Drugs (1"The Pink Sheet" June 11, 2007, In Brief). The draft guidances can be found on 2FDA's Web site
You may also be interested in...
Bioequivalence guidance accessibility
FDA releases draft guidance regarding the agency's plans to make product-specific, bioequivalence study design guidance available to the public on FDA's Web site. Currently, ANDA applicants must request guidance from the agency and wait for a response. The agency is seeking public comments for product-specific bioequivalence recommendations. FDA's Office of Generic Drugs has touted this long-awaited guidance as a means to reduce correspondence (1"The Pink Sheet" March 26, 2007, p. 14)...
IFRA Hosts Capitol Hill Scent Experience In Timeout From Policy Concerns
The International Fragrance Association North America took a break from its higher-stakes advocacy work Nov. 1 to give lawmakers and congressional staffers a "scent experience." Perfumers from six of the group's biggest members were on hand with "Scents of Home," joined by Monell Center researchers to educate attendees on the mechanics of scent and the important role it plays in people's lives.
NSF's Cosmetics Verification Program Fizzles, While EWG's Could See Second Boom
NSF International has put its cosmetic product verification program on ice due to lack of interest since its launch in April 2017. Meanwhile, more than 1,000 products from 75+ brands have earned the "EWG Verified" mark, and the NGO says interest is higher than ever following Walmart's announcement in September that it will begin pushing vendors to pursue the verification.